Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.

Maroun Bou ZerdanGennady BratslavskyJoseph JacobJeffrey RossRichard HuangAlina Basnet

Published in: Molecular diagnosis & therapy (2023)

An increased frequency of genomic alterations is observed in UBC FGFR. These have been linked to immune checkpoint inhibitor resistance. Clinical trials are needed to evaluate UBC FGFR-based biomarkers prognostic of an immune checkpoint inhibitor response. Only then can we successfully incorporate novel therapeutic strategies into the evolving landscape of UBC treatment.

Keyphrases

clinical trial
copy number
single cell
high grade
combination therapy
phase ii
gene expression
study protocol
binding protein
smoking cessation
muscle invasive bladder cancer